31 January 2012 - Canadian biOasis Technologies Inc (CVE:BTI) said on Monday that work is progressing at Texas Tech University Health Sciences Center (TTUHSC) to conduct preclinical studies to assess the pharmacokinetics of BT2111 (a proprietary conjugate of p97 and Herceptin) in animal models of breast cancer metastasis in the brain.

This programme being carried out with TTUHSC follows on the results generated at the British Columbia Cancer Research Center showing that BT2111 had better in vitro cancer killing activity than Herceptin alone and from animal studies performed at the National Research Council (Ottawa) and the iCapture Centre (Vancouver), demonstrating a 10-fold increase in BT2111 transport into the brain compared with Herceptin alone.

BT2111 is a conjugate between biOasis' Transcend brain delivery vector p97 and trastuzumab (Herceptin), a humanised monoclonal antibody used clinically in the treatment of HER2+ breast cancer.